Evidence map›Paper›PMID 33963765›Full record

ArticleInternational journal of dermatology2021

International registry of dermatological manifestations secondary to COVID-19 infection in 347 Hispanic patients from 25 countries.

Jorge Ocampo-Candiani, Cesar Jair Ramos-Cavazos, Maria Ivonne Arellano-Mendoza, Roberto Arenas-Guzmán, Angélica Beirana-Palencia, Alfredo Salmon-Demongin, Esperanza Welsh-Hernández, Horacio A Cabo, Minerva Gómez-Flores, Judith Dominguez-Cherit and 13 more

Abstract read
In one paragraph

Article in International journal of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Jorge Ocampo-CandianiUniversidad Autónoma de Nuevo León, Servicio de Dermatología, Hospital Universitario "Dr. José E. González", Monterrey, México.ORCID https://orcid.org/0000-0002-0213-0031
Cesar Jair Ramos-CavazosUniversidad Autónoma de Nuevo León, Servicio de Dermatología, Hospital Universitario "Dr. José E. González", Monterrey, México.ORCID https://orcid.org/0000-0003-3291-0992
Maria Ivonne Arellano-MendozaDepartamento de Dermatología, Hospital General de México, Ciudad de México, México.
Roberto Arenas-GuzmánHospital "Manuel Gea González", Secretaría de Salud, Ciudad de México, México.ORCID https://orcid.org/0000-0002-2992-9564
Angélica Beirana-PalenciaSociedad Mexicana de Dermatología, Ciudad de México, México.
Alfredo Salmon-DemonginDepartamento editorial Latin American Journal of Clinical Sciences and Medical Technology, Ciudad de México, México.
Esperanza Welsh-HernándezAcademia Mexicana de Dermatología, Monterrey, México.
Horacio A CaboDepartamento de Dermatología, Universidad de Buenos Aires, Buenos Aires, Argentina.
Minerva Gómez-FloresUniversidad Autónoma de Nuevo León, Servicio de Dermatología, Hospital Universitario "Dr. José E. González", Monterrey, México.ORCID https://orcid.org/0000-0003-4212-0185
Judith Dominguez-CheritInstituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán" Ciudad de México, México.ORCID https://orcid.org/0000-0003-3542-4615
Paulo Ricardo CriadoFaculdade de Medicina do ABC, Santo André, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-9785-6099
Helena Castro-LópezHospital General Regional No. 2. El Marqués, IMSS, Querétaro, México.
Abraham Benjamin Alfaro-SánchezAcademia Mexicana de Dermatología, Monterrey, México.
Alejandro García-VargasHospital de la Heroica Escuela Naval, Ignacio Zaragoza, Veracruz Llave, Mexico.
Emilia N Cohen-SabbanServicio de Dermatología, Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina.
Manuel Del SolarServicio de Dermatología, Hospital Cayetano Heredia, Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Perú.
Félix FichDepartamento de Dermatología, Pontificia Universidad Católica de Chile, Santiago, Chile.
Gastón GalimbertiSección de Oncología Cutánea y Cirugía de Mohs, Hospital italiano, Buenos Aires, Argentina.ORCID https://orcid.org/0000-0003-3537-9148
Carlos Fernando GattiInstituto de Medicina Cutánea de Buenos Aires, Buenos Aires, Argentina.
José Luis López-EstebaranzServicio de Dermatología, Hospital Universitario Fundación Alcorcón, Madrid, España.ORCID https://orcid.org/0000-0002-8816-1989
Omar LupiUniversidade Federal do Rio de Janeiro (UFRJ), Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Policlínica Geral do Rio de Janeiro (PGRJ), Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0002-2628-2312
Miguel Olmos-PérezDepartamento de Dermatología, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia.
Ricardo Pérez-AlfonzoDepartamento de Dermatología, Instituto de Biomedicina, Universidad Central de Venezuela, Hospital Vargas Clínica El Ávila, Caracas, Venezuela.ORCID https://orcid.org/0000-0002-3661-0885

Funding

Galderma
6 · The paper itself

Abstract

backgroundThe infection by coronavirus disease 2019 (COVID-19) has been associated with multiple cutaneous manifestations, although characterization of them in Hispanic patients with darker skin phototypes is lacking. The objective of this study is to characterize the clinical dermatological manifestations associated with COVID-19 infection in cases with few or without general symptoms in patients from Latin America.

methodsCross-sectional study using a questionnaire that was made for health professionals (physicians with a specialty in dermatology) to investigate dermatological lesions associated with COVID-19 infection in patients from 25 countries of Latin America. The survey was active from June 9 to July 30, 2020.

resultsIn this study, information was collected from a total of 347 patients. We found a female gender predominance: 179/347 (51.6%). The mean age at presentation was 40.87 years. The most frequent dermatological manifestations were maculopapular rash and urticarial lesions, followed by papulovesicular lesions, vesicular lesions, chilblain-like lesions, papular lesions, ecchymosis, petechial purpura, pityriasis rosea-like lesions, pruritus, palmoplantar dysesthesias, transient livedo, acral necrosis, palpable purpura, livedo racemosa, and retiform purpura. As far as we know, there are no previous reports of pruritus and palmoplantar dysesthesias.

conclusionsThis registry emphasizes skin manifestations as an important criterion for establishing the diagnosis of COVID-19 infection in Latin American countries. This information will be useful for the early identification of suspected cases by health professionals (dermatologists and nondermatologists) and will allow contact tracing to mitigate the impact on health systems at different levels.

Indexed as

COVID-19Cross-Sectional StudiesFemaleHispanic or LatinoHumansRegistriesSARS-CoV-2

Identifiers

PMID33963765
PMCPMC8239526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.